Eisai Co., Ltd.

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
6,259 ^JPY	+2.79%		+6.01%	-11.25%

Apr. 24	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE
Apr. 23	Alzheimer's drug adoption in US slowed by doctors' skepticism	RE

EISAI : TO SUPPORT COUNTER MEASURES FOR CHINA'S NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA

January 31, 2020 at 07:59 am EST

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that it has decided to offer a donation of 1 million yuan to Wuhan Charity Federation, a non-profit organization, through its Chinese subsidiary to support counter measures against the outbreak of Novel Coronavirus-associated pneumonia, which is spreading mainly in Wuhan City, Hubei Province in China.

In addition, medicines will be provided for medical institutions.

Eisai sincerely pray for the early recovery of Novel Coronavirus-associated pneumonia patients and the end of virus infection in China.

Contact:

Tel: +81-(0)3-3817-5120

Latest news about Eisai Co., Ltd.

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	CI
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
Lifenet to Launch Dementia-Focused Insurance Product in April	Mar. 22	MT
Jefferies Adjusts Eisai’s Price Target to 6,300 Yen From 7,500 Yen, Keeps at Hold	Mar. 11	MT
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel	Mar. 08	RE
Transcript : Eisai Co., Ltd. - Special Call	Mar. 07
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected	Mar. 07	RE
RMed Online Ltd. announced that it has received funding from Eisai Co., Ltd.	Mar. 05	CI
Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	Feb. 22	CI
Biogen expects to return to profit growth this year	Feb. 13	RE
Proteins may predict who will get dementia 10 years later, study finds	Feb. 12	RE
Eisai’s Attributable Profit Down 25.6% in Fiscal Nine Months	Feb. 06	MT
Transcript : Eisai Co., Ltd., Q3 2024 Earnings Call, Feb 06, 2024	Feb. 06
Eisai to Roll Out Alzheimer's Drug in China	Feb. 05	MT
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04	RE
Biogen to discontinue development of older Alzheimer's drug Aduhelm	Jan. 31	RE
Eisai's China Arm Seen to Launch Alzheimer's Treatment in July	Jan. 18	MT
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	Jan. 11	MT
Biogen, Eisai Receive Approval for Alzheimer's Treatment Leqembi in China	Jan. 10	MT
Eisai Co. Receives Approval in China for Alzheimer’s Drug, Eyes July Sales Launch	Jan. 09	MT

Chart Eisai Co., Ltd.

Duration

Period

More charts

Company Profile

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Eisai Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,259 JPY

Average target price

8,193 JPY

Spread / Average Target

+30.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EISAI CO., LTD.	-11.25%	11.26B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.49%	358B
MERCK & CO., INC.	+19.25%	322B
ABBVIE INC.	+8.12%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.67%	149B
AMGEN INC.	-6.56%	146B

Other Pharmaceuticals

Eisai Co., Ltd.

Equities

4523

JP3160400002

Pharmaceuticals

EISAI : TO SUPPORT COUNTER MEASURES FOR CHINA'S NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA

EPS Revisions